<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02777580</url>
  </required_header>
  <id_info>
    <org_study_id>LRD.2016.STREAM2</org_study_id>
    <nct_id>NCT02777580</nct_id>
  </id_info>
  <brief_title>STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction</brief_title>
  <acronym>STREAM-2</acronym>
  <official_title>STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Life Sciences Research Partners</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fund for Clinical Cardiovascular Research at LRD</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In elderly patients ≥ 70yrs with acute ST-elevation myocardial infarction randomised within 3
      hours of onset of symptoms the efficacy and safety of a strategy of early fibrinolytic
      treatment with half-dose tenecteplase and additional antiplatelet therapy with a loading dose
      of 300 mg clopidogrel, aspirin and coupled with antithrombin therapy followed by
      catheterisation within 6-24 hours or rescue coronary intervention as required, will be
      compared to a strategy of primary PCI with a P2Y12 antagonist and antithrombin treatment
      according to local standards.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients achieving ≥ 50 % ST-segment resolution before and after PCI; needing rescue PCI; demonstrating TIMI flow grades (0,1,2,3); with aborted MI.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with stroke (total, intracranial haemorrhage, ischaemic, haemorrhagic conversion) and non-intracranial bleeds. Number of patients with serious cardiac events.</measure>
    <time_frame>30 days</time_frame>
    <description>Serious cardiac events (e.g. death , congestive heart failure, reinfarction, resuscitated ventricular fibrillation, repeat target vessel recanalization, stent thrombosis, total AV block etc).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite endpoints (e.g. death, shock, heart failure and recurrent MI) will be assessed as described in the statistical analytical plan.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Pharmaco-invasive strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Half-dose tenecteplase and additional antiplatelet therapy with a loading dose of 300 mg clopidogrel, aspirin and coupled with antithrombin therapy followed by coronary angiography within 6-24 hours or rescue coronary intervention as required.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard primary PCI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Primary PCI with a P2Y12 antagonist and antithrombin treatment according to local standards.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenecteplase</intervention_name>
    <description>Half dose Tenecteplase</description>
    <arm_group_label>Pharmaco-invasive strategy</arm_group_label>
    <other_name>TNKase</other_name>
    <other_name>Metalyse</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>300 mg p.o. initial loading dose. Maintenance dose of 75 mg p.o. once daily. The maintenance dose of Clopidogrel (75 mg p.o. per day) should be continued for 1 year.</description>
    <arm_group_label>Pharmaco-invasive strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Coronary angiography</intervention_name>
    <description>Coronary angiography followed by PCI or CABG if required, rescue PCI if required</description>
    <arm_group_label>Pharmaco-invasive strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Primary PCI</intervention_name>
    <description>Primary PCI accoring to local standards</description>
    <arm_group_label>Standard primary PCI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age equal or greater than 70 years

          2. Onset of symptoms &lt; 3 hours prior to randomisation

          3. 12-lead ECG indicative of an acute STEMI (ST-elevation will be measured from the J
             point; scale: 1 mm per 0.1 mV):

               -  ≥ 2 mm ST-elevation across 2 contiguous precordial leads (V1-V6) or leads I and
                  aVL for a minimum combined total of ≥ 4 mm ST-elevation or

               -  ≥ 2 mm ST-elevation in 2 contiguous inferior leads (II, III, aVF) for a minimum
                  combined total of ≥ 4 mm ST-elevation

          4. Informed consent received

        Exclusion Criteria:

          1. 1. Expected performance of PCI &lt; 60 minutes from diagnosis (qualifying ECG) or
             inability to arrive at the catheterisation laboratory within 3 hours

          2. Previous CABG

          3. Left bundle branch block or ventricular pacing

          4. Patients with cardiogenic shock - Killip Class 4

          5. Patients with a body weight &lt; 55 kg (known or estimated)

          6. Uncontrolled hypertension, defined as sustained blood pressure ≥ 180/110 mm Hg
             (systolic BP ≥ 180 mm Hg and/or diastolic BP ≥ 110 mm Hg) prior to randomisation

          7. Known prior stroke or TIA

          8. Recent administration of any i.v. or s.c. anticoagulation within 12 hours, including
             unfractionated heparin, enoxaparin, and/or bivalirudin or current use of oral
             anticoagulation (i.e. warfarin or a NOACs)

          9. Active bleeding or known bleeding disorder/diathesis

         10. Known history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial
             or spinal surgery) or recent trauma to the head or cranium (i.e. &lt; 3 months)

         11. Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2
             months (this includes any trauma associated with the current myocardial infarction)

         12. Clinical diagnosis associated with increased risk of bleeding including known active
             peptic ulceration and/or neoplasm with increased bleeding risk

         13. Prolonged cardiopulmonary resuscitation (&gt; 2 minutes) within the past 2 weeks

         14. Known acute pericarditis and/or subacute bacterial endocarditis

         15. Known acute pancreatitis or known severe hepatic dysfunction, including hepatic
             failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis

         16. Dementia

         17. Known severe renal insufficiency

         18. Previous enrolment in this study or treatment with an investigational drug or device
             under another study protocol in the past 7 days

         19. Known allergic reactions to tenecteplase, clopidogrel, enoxaparin and aspirin

         20. Inability to follow the protocol and comply with follow-up requirements or any other
             reason that the investigator feels would place the patient at increased risk if the
             investigational therapy is initiated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frans Van de Werf, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Katholieke Universiteit Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Armstrong, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alberta, Edmonton, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Sinnaeve, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Welsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta, Edmonton, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Patrick Goldstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lille University Hospital, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Katleen Vandenberghe, PhD</last_name>
    <phone>+3216342111</phone>
    <email>katleen.vandenberghe@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Luyten, MD</last_name>
    <phone>+3216342111</phone>
    <email>anne.luyten@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Avicenne / Services SAMU et Cardiologie</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric Lapostolle, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Chateauroux</name>
      <address>
        <city>Châteauroux</city>
        <zip>36019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis Soulat, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Versailles</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yves Lambert, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick Goldstein, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F; STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013 Apr 11;368(15):1379-87. doi: 10.1056/NEJMoa1301092. Epub 2013 Mar 10.</citation>
    <PMID>23473396</PMID>
  </reference>
  <reference>
    <citation>Sinnaeve PR, Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Lambert Y, Danays T, Soulat L, Halvorsen S, Ortiz FR, Vandenberghe K, Regelin A, Bluhmki E, Bogaerts K, Van de Werf F; STREAM investigators. ST-segment-elevation myocardial infarction patients randomized to a pharmaco-invasive strategy or primary percutaneous coronary intervention: Strategic Reperfusion Early After Myocardial Infarction (STREAM) 1-year mortality follow-up. Circulation. 2014 Sep 30;130(14):1139-45. doi: 10.1161/CIRCULATIONAHA.114.009570. Epub 2014 Aug 26.</citation>
    <PMID>25161043</PMID>
  </reference>
  <reference>
    <citation>Dianati Maleki N, Van de Werf F, Goldstein P, Adgey JA, Lambert Y, Sulimov V, Rosell-Ortiz F, Gershlick AH, Zheng Y, Westerhout CM, Armstrong PW. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. Heart. 2014 Oct;100(19):1543-9. doi: 10.1136/heartjnl-2014-306023. Epub 2014 Jun 10.</citation>
    <PMID>24916050</PMID>
  </reference>
  <reference>
    <citation>Sinnaeve PR, Danays T, Bogaerts K, Van de Werf F, Armstrong PW. Drug Treatment of STEMI in the Elderly: Focus on Fibrinolytic Therapy and Insights from the STREAM Trial. Drugs Aging. 2016 Feb;33(2):109-18. doi: 10.1007/s40266-016-0345-6. Review.</citation>
    <PMID>26849132</PMID>
  </reference>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2016</study_first_submitted>
  <study_first_submitted_qc>May 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2016</study_first_posted>
  <last_update_submitted>October 24, 2017</last_update_submitted>
  <last_update_submitted_qc>October 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Frans Van de Werf</investigator_full_name>
    <investigator_title>Prof Dr</investigator_title>
  </responsible_party>
  <keyword>Thrombolytic Therapy</keyword>
  <keyword>Primary PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

